Marketwise Announces Financial and Legal Advisors of the Special Committee of its Board of Directors

MARKETWISE, INC. (MKTW) filed an SEC Form 8-K — Results of Operations and Financial Condition. MarketWise Reports Q2 Billings Increase of 57% YoY to $91.2 Million and Q2 CFFO Increase of 25.7% to $22.4 million; Net Revenue of $75.8 Million and Net Loss of $2.6 Million for Second Quarter 2026; Raises FY 2026 Billings Guidance 10% to $330 million; Affirms FY 2026 Dividend Ta

MARKETWISE, INC. (MKTW) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991-financialandope.htm EX-99.1 Document MarketWise, Inc. Reports Preliminary Selected Unaudited Second Quarter Results With Paid Subscriber Growth Continuing In The Second Quarter 2026; Billings Increased 56% Year-Over-Year To Approximately $91 million ; Raises

Scotiabank kept its Sector Outperform rating on Robinhood Markets with a $124 price target, implying a 31.1% upside from the Oct 27 close. The bank cited strong growth in Robinhood's Rothera exchange and strategic customer acquisition as key drivers. Recent analyst price targets for HOOD range from $116 to $165.

Propanc Biopharma (PPCB) aims to begin patient screening for its cancer treatment PPC-001 in February 2027. The Phase 1b study will involve up to 50 patients with solid tumors in Australia. The company is finalizing clinical protocols and site assessments, with regulatory submissions planned for early 2027. PPC-001 has received FDA Orphan Drug Designation for pancreatic cancer.

Evolution Metals & Technologies Corp. (EMAT) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Evolution Metals & Technologies Confirms Delivery of All 57 ULVAC Equipment Containers to Pohang Expansion Site, with Commissioning Under Way at the Largest Expected High-Performance Rare Earth Magnet Facility Outside China Equipment secured in months against industr

SELLAS Life Sciences (SLS) completed its Phase 3 REGAL AML trial after reaching 80 deaths, triggering final analysis. The company expects to report preliminary results this quarter. The milestone reduces timing uncertainty for the trial's outcome.